Loading
Life sciences · Journal article
Frontiers in Oncology · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Alzheimer’s disease (AD) is the leading cause of dementia worldwide, characterized by progressive cognitive decline and neurodegeneration. Although amyloid-β plaques and hyperphosphorylated tau are major pathological hallmarks, increasing evidence highlights persistent neuroinflammation as a critical contributor to disease progression. Activated microglia and astrocytes, inflammatory cytokines, inflammasome activation, and dysregulated immune responses promote neuronal damage and synaptic dysfunction. Similar inflammatory mechanisms are observed in neurological disorders such as multiple sclerosis (MS) and brain tumors, suggesting shared molecular pathways linking neuroinflammation, neurodegeneration, and tumor-associated immune responses. Proteomics, transcriptomics, and multi-omics approaches provide powerful strategies to characterize disease-associated molecular signatures, signaling pathways, biomarkers, and therapeutic targets. This review summarizes key neuroinflammatory mechanisms in AD, including NF-κB, NLRP3, PI3K/Akt, MAPK, cGAS–STING, mitochondrial, lysosomal, calcium, insulin, and blood–brain barrier pathways. Recent advances in proteomic and transcriptomic profiling and their integration with genomic, epigenomic, and metabolomic data are discussed for understanding disease heterogeneity and identifying clinically relevant biomarkers. Current and emerging therapeutic strategies, including anti-Aβ antibodies, anti-inflammatory agents, selective inhibitors, dual-target compounds, PROTACs, and protein–protein interaction modulators, are also evaluated. Finally, multi-omics-based precision medicine and artificial intelligence-assisted analysis may facilitate biomarker-guided patient stratification and development of effective disease-modifying therapies.